Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) primarily indica···【more】
Release date：2026-01-20Recommended：24
Ponatinib is an oral tyrosine kinase inhibitor primarily indicated for the treat···【more】
Release date：2026-01-20Recommended：19
Ponatinib is indicated for the treatment of patients with chronic-phase chronic ···【more】
Release date：2026-01-20Recommended：16
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI), primarily indic···【more】
Release date：2026-01-20Recommended：19
The price of ponatinib varies depending on the region, specification, purchase c···【more】
Release date：2026-01-20Recommended：15
Ponatinib is a targeted therapy indicated for specific types of leukemia, such a···【more】
Release date：2026-01-20Recommended：21
Ponatinib is an oral targeted drug specifically indicated for the treatment of c···【more】
Release date：2026-01-20Recommended：17
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the U.S. ···【more】
Release date：2026-01-20Recommended：19
Ponatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI), was devel···【more】
Release date：2026-01-20Recommended：16
On March 19, Takeda announced that the U.S. Food and Drug Administration (FDA) h···【more】
Release date：2026-01-20Recommended：26
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the Phase···【more】
Release date：2026-01-20Recommended：28
During treatment with pralsetinib, it is imperative that you inform your healthc···【more】
Release date：2026-01-16Recommended：26
